VRTX
Vertex Pharmaceuticals Inc
504.70$
-0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -24.1% | -8.2% | -10.1% | -5.5% | 5.2% | 23.7% | 17.6% | 4.5% | 5.5% | 6.3% | 5.6% | 7.0% | 8.9% | 13.9% | 8.9% | 5.7% | 18.3% | 10.7% | 10.5% | 12.2% | 12.4% | 11.1% | 13.4% | 13.2% | 11.9% | 11.9% | 12.1% | 12.8% | 13.9% | 15.0% | |
| 124.1% | 108.2% | 110.1% | 105.5% | 94.8% | 76.3% | 82.4% | 95.5% | 94.5% | 93.7% | 94.4% | 93.0% | 91.1% | 86.1% | 91.1% | 94.3% | 81.7% | 89.3% | 89.5% | 87.8% | 87.6% | 88.9% | 86.6% | 86.8% | 88.1% | 88.1% | 87.9% | 87.2% | 86.1% | 85.0% | |
| 264.7% | 117.8% | 132.2% | 117.2% | 108.7% | 88.8% | 126.0% | 288.7% | 187.1% | 154.5% | 171.8% | 257.8% | 294.2% | 539.6% | 444.6% | 50.2% | 52.8% | 75.8% | 147.4% | 96.5% | 61.6% | 53.2% | 46.5% | 42.1% | 29.5% | 40.3% | 29.7% | 32.0% | 32.9% | 31.1% | |
| 59.4% | 26.0% | 40.8% | 42.4% | 35.6% | 28.3% | 30.7% | 56.5% | 41.0% | 27.3% | 26.7% | 42.6% | 58.1% | 127.6% | 131.0% | 28.4% | 24.8% | 28.3% | 49.8% | 34.2% | 23.6% | 19.9% | 18.3% | 15.8% | 12.4% | 11.1% | 9.9% | 11.5% | 13.3% | 14.5% | |
| 348.1% | 152.1% | 183.1% | 169.8% | 144.3% | 117.0% | 156.7% | 345.3% | 228.1% | 181.8% | 198.5% | 300.4% | 352.2% | 666.3% | 575.6% | 78.6% | 81.4% | 105.7% | 200.0% | 133.0% | 87.0% | 73.2% | 64.8% | 58.0% | 42.1% | 51.4% | 39.7% | 48.4% | 88.2% | 45.6% | |
| -224.1% | -43.8% | -73.0% | -64.3% | -49.5% | -54.8% | -74.2% | -382.6% | -150.7% | -93.2% | -105.9% | -210.9% | -263.6% | -601.1% | -485.5% | 8.1% | 0.2% | -74.5% | -119.3% | -45.4% | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | 36.7% | 48.2% | 38.8% | -2.1% | 39.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.7% | 0.0% | 7.7% | 12.9% | 13.4% | 2.6% | 1.1% | 1.9% | 12.6% | 8.2% | 4.8% | 2.8% | 1.1% | 1.4% | 0.9% | 0.8% | 0.6% | 0.4% | 0.3% | 0.1% | |
| -297.0% | – | – | -65.4% | -68.6% | -70.4% | -74.3% | -502.4% | -154.3% | -107.8% | -95.6% | -214.5% | -264.5% | -629.3% | -526.3% | 4.3% | -0.8% | -80.5% | -126.6% | -54.2% | -4.0% | -0.6% | 19.7% | 33.5% | 50.2% | 36.0% | 47.4% | 44.4% | 2.3% | 38.5% | |
| 76.7% | 1.4% | 1.6% | 2.3% | 1.2% | -1.1% | -6.8% | 34.8% | 28.2% | 38.3% | -8.5% | -10.8% | -17.5% | 18.9% | 13.4% | 1.4% | 2.5% | -23.8% | 1.2% | 2.9% | 1.0% | -4.3% | -48.8% | 5.2% | 6.5% | 5.1% | 10.2% | 7.7% | 7.1% | 5.7% | |
| -300.8% | -45.2% | -74.5% | -66.6% | -50.8% | -39.5% | -67.4% | -284.6% | -161.8% | -126.4% | -95.6% | -196.6% | -262.0% | -628.7% | -526.3% | 2.1% | -7.0% | -36.7% | -127.2% | -54.1% | -6.6% | 10.6% | 68.8% | 28.3% | 43.7% | 30.9% | 37.2% | 36.7% | -4.9% | 32.7% | |
| -272.9% | -35.6% | -97.3% | -71.9% | -31.6% | -58.0% | -76.4% | -382.6% | -104.7% | -71.1% | -92.2% | -193.6% | -242.8% | -586.9% | -491.7% | 9.5% | 2.8% | -45.8% | -103.2% | -39.8% | 4.4% | 4.1% | 23.2% | 37.5% | 52.9% | 38.5% | 49.7% | 46.7% | 4.4% | 40.3% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.